NOBEL MEDICUS, vol.14, no.3, pp.5-8, 2018 (ESCI)
Mutation of epidermal growth factor receptor (EGFR) is one of the targeted mutations in treatment of non-small cell lung cancer (NSCLC). Mutation of EGFR occurs in 15-40% of all patients with NSCLC. In this review, efficacy of different EGFR inhibitors used in NSCLC treatment is evaluated.